SCHEMBL24264115

SCHEMBL24264115

c1ccc(-c2nc(-c3ccc4c(c3)oc3ccc(-c5ccc6oc7ccccc7c6c5)cc34)nc(-c3cccc4oc5ccccc5c34)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G2A P14555 3/20 0.40
PLA2G4A P47712 3/20 0.40
PLA2G10 O15496 1/20 0.40
HCRTR1 O43613 1/20 0.38
CHEK2 O96017 1/20 0.37
ALDH1A1 P00352 4/20 0.37
HPGD P15428 4/20 0.37
KDM4E B2RXH2 3/20 0.37
MAPT P10636 3/20 0.37
AHR P35869 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
MMP12 P39900 2/20 0.37
MMP13 P45452 1/20 0.37
HSP90AA1 P07900 1/20 0.37
HSP90AB1 P08238 1/20 0.37
ALOX5 P09917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24097537 1.00 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10HCRTR1CHEK2
SCHEMBL24264163 1.00 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10HCRTR1CHEK2
SCHEMBL23821270 1.00 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10HCRTR1CHEK2
SCHEMBL23559216 1.00 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10HCRTR1CHEK2
SCHEMBL23821666 0.99 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10HCRTR1CHEK2
SCHEMBL24215943 0.99 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10HCRTR1CHEK2
SCHEMBL25627160 0.99 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10HCRTR1CHEK2
SCHEMBL23822529 0.99 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10HCRTR1CHEK2
SCHEMBL23822668 0.99 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10HCRTR1CHEK2
SCHEMBL25627157 0.99 PLA2G2A (0.40) PLA2G2APLA2G4APLA2G10HCRTR1CHEK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11832517-B2 Heterocyclic compound and organic light emitting device comprising same LG CHEM, LTD. (KR) 2023-11-28 US disclosed
US-11832517-B2 Heterocyclic compound and organic light emitting device comprising same LG CHEM, LTD. (KR) 2023-11-28 US disclosed
US-20220059778-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME LG CHEM, LTD. (KR) 2022-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220059778-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME CRY1, TRPC1, CYP1A1 PLA2G2A 4009/4885PLA2G4A 4120/4885PLA2G10 4539/4885
US-11832517-B2 Heterocyclic compound and organic light emitting device comprising same CRY1, TRPC1, CYP1A1 PLA2G2A 4009/4885PLA2G4A 4120/4885PLA2G10 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.